Prednisolone

EQS-News: Grünenthal reports strong 2023 results with record revenue and continued investments in R&D and acquisitions

Retrieved on: 
星期三, 四月 10, 2024
Trigeminal neuralgia, Knee, Growth, Rheumatoid arthritis, Neuropathic pain, Pain, GRM, DPN, ESG, Patient, Prednisolone, Research, Sustainalytics, Breakthrough, Glucocorticoid, Quality of life, PSNP, Research and development, Investment, Diabetic neuropathy, NOP, Kyowa Kirin, Osteoarthritis, RTX, Food, FDA, Corporation, Pharmaceutical industry

In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.

Key Points: 
  • In 2023, Grünenthal generated €1.8 billion in revenues, an increase of 10 percent over the prior year.
  • Grünenthal owns 51 percent of the new enterprise Grünenthal Meds and intends to acquire the remaining share in 2026.
  • Aachen, Germany, 25 March 2024 – Grünenthal, the leading pharmaceutical company in pain research and management, released its 2023 full-year results, announcing a double-digit revenue growth.
  • The 2023 results were driven by strong business performance in the United States, Latin America and Europe.

WILLOW BIOSCIENCES REPORTS FOURTH QUARTER AND FISCAL YEAR 2023 FINANCIALS AND OPERATIONS AND FILING OF ITS 2023 AIF

Retrieved on: 
星期四, 三月 28, 2024
Partnership, HTP, Prednisolone, Enzyme, DNA, Hydrocortisone, Budesonide, Willow, Fine chemical

Transition of R&D programs to commercial revenue: With multiple R&D programs now complete or nearing completion, the Company anticipates generating first commercial revenues from at least two products as they transition to commercial production.

Key Points: 
  • Transition of R&D programs to commercial revenue: With multiple R&D programs now complete or nearing completion, the Company anticipates generating first commercial revenues from at least two products as they transition to commercial production.
  • Commercial revenue is expected to be potentially milestone, royalty, and ingredient supply revenue.
  • Significant increase in revenues: Full year R&D revenues for 2024 are expected to increase by over 100% compared to 2023.
  • In addition, commercial stage revenue is expected to commence on multiple programs.

WILLOW PLANS FOR SIGNIFICANT GROWTH IN 2024 ON THE BACK OF A SUCCESSFUL 2023

Retrieved on: 
星期三, 一月 10, 2024
Budesonide, WLLW, DNA, Partnership, API, Outline, TSX, Acceleration, Enzyme, Hydrocortisone, HTP, UDCA, CDMO, Prednisolone, Growth, Fine chemical

"2023 was a transformative year for Willow with the successful development of our highly valuable BioOxi technology platform which we believe will support significant growth in 2024.

Key Points: 
  • "2023 was a transformative year for Willow with the successful development of our highly valuable BioOxi technology platform which we believe will support significant growth in 2024.
  • We also generated record revenue growth through partnerships and implemented a successful corporate and operational reorganization to support the future growth of Willow," said Dr. Chris Savile, Willow's President & CEO.
  • Record revenues in 2023: Revenues increased approximately 60% to an estimated $1.3 million in 2023.
  • Significant increase in revenues: Full year R&D revenues for 2024 are expected to increase by over 100% compared to 2023.

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Retrieved on: 
星期五, 一月 5, 2024
Marketing, Platinum, INN, Risk, HER2, Leukopenia, Heartburn, Woman, BRCA, Man, Nausea, DNA, Cancer, Neoplasm, Mutation, Pancreatic cancer, ADP, Prostate, Anatomy, Cell division, Cough, IIA, Diarrhea, Prostate cancer, HRD, Fatigue, Breast cancer, ATC, Platelet, Pancreas, Prednisone, Disease, Genome, Abdomen, Testosterone, PARP, Neutrophil, Bevacizumab, Appetite, Human, Anemia, Patient, Medical Subject Headings, Peritoneum, International, FIGO, Tubing (recreation), Neutropenia, Language, Castration, Dizziness, Thrombocytopenia, BRCA1, Gene, Tablet, Select, Time, Vomiting, Ovary, Prednisolone, X-ray, Ovarian cancer, Headache, BRCA2, European Medicines Agency, Indigestion, Periodic breathing, Birth control

Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Lynparza, olaparib, Date of authorisation: 16/12/2014, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Retrieved on: 
星期四, 一月 4, 2024
Marketing, BAL, PV, INN, Risk, MPA, Shivering, DLBCL, CD20, BLL, PML, Pemphigus vulgaris, Cancer, Inflammation, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Nose, Ageing, Allergy, Glucocorticoid, CLL, NHL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Overview, B cell, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, Lymphocytosis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Rixathon, rituximab, Date of authorisation: 15/06/2017, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 27, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Patient, Medical Subject Headings, Marketing, Prednisolone, European Commission, Liver, Agency, Survival, CYP17, INN, Woman, Docetaxel, Fracture, ATC, Male, Hormone, Hypersensitivity, International, Cough, Man, European, Prednisone, Disease, Language, Prostate cancer, Cerebral edema, Eating, Castration, Cancer, Urinary tract infection, Neoplasm, Testosterone, Prostate, Abiraterone acetate, European Medicines Agency, Food, Tablet, Growth, Select, Anatomy, Medicine, IIA, Hypokalemia

Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 27, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Zytiga, abiraterone, Date of authorisation: 05/09/2011, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, INN, Risk, MPA, Shivering, CD20, PML, ACR20, Pemphigus vulgaris, Cancer, Inflammation, Death, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Bone marrow, GPA, Disease, Allergy, Hepatitis B virus, CLL, NHL, Safety, Arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Antibody, Vincristine, International, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Encephalitis, Medicine, B cell, Prednisolone, Autoimmune disease, CHOP, Blood, Rheumatoid arthritis, Vasculitis, European Medicines Agency, Doxorubicin, Cell, Chronic lymphocytic leukemia, Resuscitation, Medical device

Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Blitzima, rituximab, Date of authorisation: 13/07/2017, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, INN, Risk, MPA, Shivering, CD20, PML, ACR20, Pemphigus vulgaris, Cancer, Inflammation, Death, Infection, Anatomy, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Pemphigus, Allergy, B cell, Hepatitis B virus, Glucocorticoid, NHL, CLL, Safety, Rheumatoid arthritis, Arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Language, Blood, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, Methotrexate, Prednisolone, Autoimmune disease, TNF, CHOP, Vasculitis, European Medicines Agency, Doxorubicin, Cell, Chronic lymphocytic leukemia, Resuscitation, DMARD, Pharmaceutical industry

Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Truxima, rituximab, Date of authorisation: 17/02/2017, Revision: 21, Status: Authorised

Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 51, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Stomach, Liver, Medical Subject Headings, Diarrhea, Marketing, Prostate cancer, Neck, Prednisolone, Stomatitis, Breast, INN, Cyclophosphamide, HER2, Breast cancer, ATC, Trastuzumab, Hair loss, International, Stomach cancer, Prednisone, Lung cancer, Weakness, Neutropenia, Nausea, Language, Mouth, Cisplatin, Cancer, Inflammation, Head, Testosterone, Neoplasm, Dexamethasone, Neutrophil, Blood, Non-small-cell lung cancer, Capecitabine, European Medicines Agency, Skeleton, Fluorouracil, Doxorubicin, Select, Cell, Patient, Anatomy, Medicine, Anemia, Vomiting, IIA, Prostate, Medical imaging

Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 51, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Taxotere, docetaxel, Date of authorisation: 27/11/1995, Revision: 51, Status: Authorised

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Retrieved on: 
星期二, 一月 2, 2024
Marketing, PV, INN, Risk, MPA, Shivering, CD20, PML, Pemphigus vulgaris, Inflammation, Infection, Anatomy, Lymphoma, IIA, Skin, Chills, Fever, ATC, Joint, Bone marrow, GPA, Disease, Nose, Allergy, Glucocorticoid, NHL, CLL, Safety, Rheumatoid arthritis, Patient, Medical Subject Headings, Cyclophosphamide, Immune system, Granuloma, Antibody, Vincristine, International, Arthritis, Language, Mouth, Follicular lymphoma, Microscopic polyangiitis, Select, B cell, Methotrexate, Prednisolone, TNF, CHOP, Blood, Vasculitis, European Medicines Agency, Doxorubicin, Chronic lymphocytic leukemia, DMARD, Medical device

Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ruxience, rituximab, Date of authorisation: 01/04/2020, Revision: 12, Status: Authorised